Download presentation
Presentation is loading. Please wait.
Published byAgus Irawan Modified over 5 years ago
1
Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. A, schematic representation of the in vivo experimental procedure. NOG mice were inoculated with 5 × 105 Raji-ffluc cells via tail-vein injection on day 0. On day 7, mice were treated with either untransduced CD8+ T cells, Tet-CD19CAR T cells with/without Dox, or CD19CAR-OR T cells. The tumor burden of the mice was then assessed weekly using bioluminescence imaging (BLI). B, BLI of mice bearing Raji-ffluc tumors. Mice treated with Tet-CD19CAR T cells in the presence of Dox showed statistically significant tumor regression. On the other hand, Tet-CD19CAR T cells without Dox could not suppress tumor growth. Data are representative of three independent experiments using three independent Tet-CD19CAR T-cell lines. C, tumor flux in individual mice on days 7, 14, 21, and 28 of inoculation of the Raji-ffluc cells. Tumor flux was calculated as the sum of the tumor signal intensity of the entire body following a 30-second exposure time. Mice treated with Tet-CD19CAR T cells in the presence of Dox showed statistically significant tumor regression compared with mice treated with Tet-CD19CAR T cells without Dox (**, P < 0.01, one-way ANOVA). The statistically significant difference was observed on days 21 and 28. Data are plotted as means ± SEM. D, Kaplan–Meier curves of the survival of mice treated with Dox(+) Tet-CD19CAR T cells or Dox(−) Tet-CD19CAR T cells. Mice treated with Dox(+) Tet-CD19CAR T cells showed significantly prolonged survival compared with mice treated with Dox(−) Tet-CD19CAR T cells (****, P < , log-rank test). Data were pooled from three independent experiments with Tet-CD19CAR T cells from three donors, including 9 to 12 mice per group in C and D. Reona Sakemura et al. Cancer Immunol Res 2016;4: ©2016 by American Association for Cancer Research
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.